13 August 2018 - Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Galafold - approved on Friday by U.S. regulators - is the first new Fabry disease treatment in the country in over 15 years, and will compete with Sanofi's infused Fabrazyme, which has an average U.S. list price of $340,000 for adults, according to Amicus.

Sanofi, however, says Fabrazyme’s price is closer to $290,000, when accounting for paediatric patients who tend to use less of the drug because of their weight. The French drugmaker did not detail drug prices separately for adults and children.

Read Reuters article